Ultragenyx Pharmaceutical Inc. (RARE): Form 8-K filed 2026-11-03

Items reported

Item 2.01: Completion of Acquisition or Disposition of Assets
The company completed the acquisition or disposition of a significant amount of assets, including a business. The report covers the date, the assets, the counterparty and the consideration.
Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed".
Item 2.05: Cost Associated with Exit or Disposal Activities
The company committed to an exit or disposal plan, such as a restructuring, facility closure or workforce reduction, under which it expects to incur material charges.
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Type	Description	Document
8-K	8-K	rare-20261030.htm
EX-99.1	EX-99.1	rare-ex99_1.htm

This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.